FDA Clearance: World's First Human Clinical Trial of Embryonic Stem Cell Therapy

[Justin]

Continued...

About Geron
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem (hESC) cell-based therapeutics. The company has received FDA clearance to begin the world's first human clinical trial of a hESC-based therapy: GRNOPC1 for acute spinal cord injury. For more information, visit human embryonic stem cell-based therapeutics | biopharmaceuticals | cancer | telomerase | human embryonic stem cell | vaccine | Geron.

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release regarding potential applications of Geron's human embryonic stem cell technology constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron's periodic reports, including the quarterly report on Form 10-Q for the quarter ended September 30, 2008.

CONTACTS:
Media: David Schull, Russo Partners, LLC, 858-717-2310, david.schull@russopartnersllc.com
At Geron: Anna Krassowska, Investor and Media Relations, 650-473-7765, info@geron.com

[Justin]

Videos and more information here: Geron Clinical Trial of GRNOPC1